Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (MDR1) gene

Abstract Resistance to chemotherapy hinders the successful treatment of acute lymphoblastic leukemia (ALL). The multi-drug resistance-1 (MDR1/ABCB1) gene encodes P‐glycoprotein (P-gp), which plays an important role in chemoresistance; however, its transcriptional regulation remains unclear. We investigated the role of YY1 in the regulation of MDR1 and its relation to ALL outcomes. Analysis of the MDR1 promoter revealed four putative YY1-binding sites, which we analyzed using a reporter system and ChIP analysis. YY1 silencing resulted in the inhibition of MDR1 expression and function. The clinical roles of YY1 and MDR1 expression were evaluated in children with ALL. Expression of both proteins was increased in ALL patients compared to controls. We identified a positive correlation between YY1 and MDR1 expression. High levels of YY1 were associated with decreased overall survival. Our results demonstrated that YY1 regulates the transcription of MDR1. Therefore, YY1 may serve as a useful prognostic and/or therapeutic target.

[1]  Y. Mizutani,et al.  Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. , 2005, Biochemical and biophysical research communications.

[2]  S. Khoo,et al.  Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna , 2004, Antiviral therapy.

[3]  K. Kohno,et al.  Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.

[4]  J. Philippé,et al.  Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. , 2006, European journal of cancer.

[5]  Kazushi Inoue,et al.  The oncogenic role of Yin Yang 1. , 2011, Critical reviews in oncogenesis.

[6]  K. Scotto.  Transcriptional regulation of ABC drug transporters , 2003, Oncogene.

[7]  I. Pastan,et al.  Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. , 1990, The Journal of biological chemistry.

[8]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[9]  Xiaolei Wang,et al.  p38 MAPK-dependent and YY1-mediated chemokine receptors CCR5 and CXCR4 up-regulation in U937 cell line infected by Mycobacterium tuberculosis or Actinobacillus actinomycetemcomitans. , 2005, Biochemical and biophysical research communications.

[10]  W. Schmidt-Heck,et al.  Cadmium, cobalt and lead cause stress response, cell cycle deregulation and increased steroid as well as xenobiotic metabolism in primary normal human bronchial epithelial cells which is coordinated by at least nine transcription factors , 2008, Archives of Toxicology.

[11]  E. Schuetz,et al.  p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  David R. Liu,et al.  Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins , 2009, Proceedings of the National Academy of Sciences.

[13]  I. Roninson,et al.  Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. , 1993, Journal of the National Cancer Institute.

[14]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[15]  L. O’Driscoll,et al.  Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis , 2010, British Journal of Cancer.

[16]  S. Grossman,et al.  Yin Yang 1 Is a Negative Regulator of p53 , 2004, Cell.

[17]  B. Bonavida,et al.  Nitric Oxide Inhibits the Transcription Repressor Yin-Yang 1 Binding Activity at the Silencer Region of the Fas Promoter: A Pivotal Role for Nitric Oxide in the Up-Regulation of Fas Gene Expression in Human Tumor Cells1 , 2001, The Journal of Immunology.

[18]  S. Zhao,et al.  Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. , 1992, Blood.

[19]  A. Zelenetz,et al.  Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  I. Roots,et al.  Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene , 2003, European Journal of Clinical Investigation.

[21]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[22]  S. Kato,et al.  Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. , 1990, The Journal of biological chemistry.

[23]  K. Calame,et al.  Yin-yang 1 activates the c-myc promoter , 1993, Molecular and cellular biology.

[24]  V. Alakhov,et al.  Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. , 1996, Cancer research.

[25]  M. Bucan,et al.  Promoter features related to tissue specificity as measured by Shannon entropy , 2005, Genome Biology.

[26]  B. Bonavida,et al.  Involvement of the TNF-α autocrine–paracrine loop, via NF-κB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis , 2006 .

[27]  D. Männel,et al.  Isolation and functional characterization of the mouse p75 TNF receptor promoter. , 1998, Genomics.

[28]  D. Spandidos,et al.  Yin Yang 1 expression in human tumors , 2010, Cell cycle.

[29]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[30]  B. Bonavida,et al.  Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. , 2006, Clinical immunology.

[31]  K. Scotto,et al.  Transcriptional Regulation of the MDR1 Gene by Histone Acetyltransferase and Deacetylase Is Mediated by NF-Y , 1998, Molecular and Cellular Biology.

[32]  O. Legrand,et al.  MDR1/P-glycoprotein in haematological neoplasms. , 1996, European journal of cancer.

[33]  O. Legrand,et al.  Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. , 1992, Leukemia & lymphoma.

[34]  Michael C. Montalto,et al.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. , 2002, Cancer research.

[35]  M. Moriuchi,et al.  YY1 Transcription Factor Down-regulates Expression of CCR5, a Major Coreceptor for HIV-1* , 2003, The Journal of Biological Chemistry.

[36]  S. Horvath,et al.  Expression of transcription factor Yin Yang 1 in prostate cancer. , 2005, International journal of oncology.

[37]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[38]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Burt,et al.  Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  T Terwilliger,et al.  Acute lymphoblastic leukemia: a comprehensive review and 2017 update , 2017, Blood Cancer Journal.

[41]  A. Suminoe,et al.  Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. , 2007, Leukemia research.

[42]  A. Faussat,et al.  Expression of resistance genes in acute leukemia. , 1994, Leukemia & lymphoma.

[43]  K. Scotto,et al.  Transcription of the multidrug resistance gene MDR1: a therapeutic target. , 2001, Molecular interventions.

[44]  D. Steinbach,et al.  Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML , 2003, Leukemia.

[45]  A. Abbruzzese,et al.  Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia , 2005, Cancer biology & therapy.

[46]  M. Daidone,et al.  Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. , 1994, European journal of cancer.

[47]  Kimura Yasuhisa,et al.  Mechanism of multidrug recognition by MDR1/ABCB1 , 2007 .

[48]  Johnson Ra,et al.  Transcription of the multidrug resistance gene MDR1: a therapeutic target. , 2001 .

[49]  I. Pastan,et al.  Genetic analysis of the multidrug transporter. , 1995, Annual review of genetics.

[50]  K. Ueda,et al.  Mechanism of multidrug recognition by MDR1/ABCB1. , 2007, Cancer science.

[51]  Je-Hwan Lee,et al.  Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia , 2006, Journal of Korean medical science.

[52]  D. Spandidos,et al.  Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 , 2007, Molecular Cancer Therapeutics.

[53]  T. Sakaeda,et al.  MDR1 genotype-related pharmacokinetics and pharmacodynamics. , 2002, Biological & pharmaceutical bulletin.

[54]  B. Bonavida,et al.  Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. , 2013, Nitric oxide : biology and chemistry.

[55]  A. Janowska-Wieczorek,et al.  Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia , 1989, British journal of haematology.

[56]  M. Imamura,et al.  Immunohistochemical Localization of P‐Glycoprotein and Expression of the Multidrug Resistance‐1 Gene in Human Pancreatic Cancer: Relevance to Indicator of Better Prognosis , 1996, Japanese journal of cancer research : Gann.

[57]  J. Roganovic,et al.  Epidemiology of childhood cancer. , 1999, IARC scientific publications.

[58]  H. Sather,et al.  Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  S. Hanada,et al.  Expression of the multidrug transporter, P‐glycoprotein, in acute leukemia cells and correlation to clinical drug resistance , 1990, Cancer.

[60]  H. Miao,et al.  Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia , 2012, Archives of medical science : AMS.

[61]  L. Rocha-Zavaleta,et al.  Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL , 2013, Leukemia & lymphoma.

[62]  K. Scotto,et al.  Transcriptional Activation of the MDR1 Gene by UV Irradiation , 2000, The Journal of Biological Chemistry.